A prescription drugmaker is planning to begin manufacturing its own versions of key medications in a big way, a big step toward turning its manufacturing operations into a global pharmacy.
The future is now, a new drugmaker CEO said Monday.
The move would be a dramatic shift for a pharmacy that has struggled to compete in a world where drug prices are soaring and there are no obvious alternatives.
It could also spark new businesses and new opportunities for drugmakers, including those who want to help drugmakers develop more complex drugs.
Antony Rifkin, president of Aventis Pharmaceuticals, said the company has secured the rights to make a brand of drug that is the generic equivalent of generics from the American Red Cross and a company called Cipla.
It also plans to make more generic versions of some drugs, including the painkiller oxycodone, he said.
Cipla and Aventus have been working for years to create a global version of a drug called oxycodan.
But Rifkins said the Aventes version would be more complex.
The Aventics brand is a brand-name generic of OxyContin, and it’s a little bit different from the generic versions that are used around the world.
It will be different in terms of how it’s packaged, it will be slightly different, but the same basic drug. “
It’s the equivalent of a branded drug.
It will be different in terms of how it’s packaged, it will be slightly different, but the same basic drug.
We’re going to be selling it at a much higher price than a branded version.”
Aventis would manufacture its own generic versions in its factory in China and elsewhere in the world, he added.
It would also be the first generic version of one of the top-selling drugs in the United States, according to data from the Food and Drug Administration.
It’s a huge milestone for the company, which has been struggling to compete with generics for years.
It recently announced it had raised $6.8 billion from an undisclosed buyer.
Aventi, which was founded in 1892, is the third-largest drugmaker in the U-S.
behind Ciplas parent company Aventia and Valeant Pharmaceuticals.
The company is the largest private-equity company in the country, with a market value of $13.7 billion.
The company plans to build its own factories and produce its own drugs, said Rifkys brother, Richard.
Richard Rifka is CEO of Amedis.
Aventi has been able to compete successfully in the past, Rifkos said, by using different manufacturing processes and using cheaper components.
It has not been able, he continued, to compete effectively in the market with generic versions.
“We have to compete at a price that makes sense to us, that makes us competitive,” Riffkin said.
The price of a generic drug is $10.50 a pill, and a brand is $20.
But Aventys price is $100 a pill.
It would be cheaper to make the generic version, and the price could be lowered if it is found to be more effective, Richard Riffka said.
“That is a great opportunity to start a business and be able to say, ‘Oh, we know that we can make this cheaper and this effective, and this is a cost that can be lowered and make this more affordable,'” he said, adding that it could also help the company’s bottom line.
Aveis has been trying to compete globally since it was founded more than 50 years ago.
Avedis made more than $100 billion in sales from its pharmaceutical businesses.
The group’s chief executive, Stephen Karpeles, has said it is investing $10 billion into drug development, including $1 billion to develop an experimental painkiller.
Richard Rifki said that drug companies like Avents, Valeant and Ciplax have struggled in the years since they were founded, but now they are coming back.
“The market is very, very small.
And the companies are starting to come back.
They have found ways to compete,” he said at a news conference last week.
Rifkins also pointed out that generics are a big market for other drugmakers.
Generic versions of Oxycontin, for example, have a higher mortality rate than brand versions.
A generic version is cheaper and less addictive, but it can cause side effects.
A branded version is more expensive and more addictive, and can cause health problems.